Some drop-the-loser designs for monitoring multiple doses

Statistics in Medicine

Volumn 29, Issue 17, 2010, Pages 1793-1807

  Chen, Y H Joshua ^a   DeMets, David L ^b   Lan, K K Gordon ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alpha spending function; Drop the loser; Futility; Group sequential

Indexed keywords

ARTICLE; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL DESIGN; MATHEMATICAL ANALYSIS; MULTIPLE DRUG DOSE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; STOCHASTIC PROCESSES;

EID: 77955170593     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3958     Document Type: Article

References (30)

1. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Controlled Clinical Trials 1993; 14:183-197. (Pubitemid 23197808)
2. Ellenberg S, Eisenberger MA. An efficient design for phase II studies of combination chemotherapies. Cancer Treatment Reports 1985; 69:1147-1154.
3. Thall P, Simon R, Ellenberg S. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-547.
4. Storer BE. A sequential phase II/III trial for binary outcomes. Statistics in Medicine 1990; 9:229-235.
5. Schaid DJ, Wieand S, Therneau TM. Optimal two-stage screening deigns for survival comparisons. Biometrika 1990; 77:659-663.
6. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848. (Pubitemid 29364054)
7. Shen LJ. An improved method of evaluating drug effect in a multiple dose clinical trial. Statistics in Medicine 2001; 20:1913-1929.
8. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703. (Pubitemid 36266961)
9. Liu Q, Pledger GW. Phase 2 and 3 combination designs to accelerate drug development. Journal of American Statistical Association 2005; 100:493-502. (Pubitemid 40816587)
10. KÄonig F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment selection. Statistics in Medicine 2008; 17:1612-1625. (Pubitemid 351566086)
11. Follmann DA, Proschan MA, Geller NL. Monitoring pairwise comparisons in multi-armed clinical trials. Biometrics 1994; 50:325-336. (Pubitemid 24230613)
12. Hughes M. Stopping guidelines for clinical trials multiple treatments. Statistics in Medicine 1993; 12:901-915. (Pubitemid 23184779)
13. Hellmich M. Monitoring clinical trials with multiple arms. Biometrics 2001; 57:892-898. (Pubitemid 32801187)
14. DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982; 69:661-663.
15. Emerson SS, Fleming TR. Symmetric group sequential test designs. Biometrics 1989; 45:905-932.
16. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. Journal of Statistical Planning and Inference 1994; 42:19-35.
17. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-199. (Pubitemid 8145484)
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
20. Kim K, DeMets DL. Sample size determination for group sequential clinical trials with immediate response. Statistics in Medicine 1992; 11:1391-1399.
21. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal of Medicine 2007; 357:2109-2122.
22. Reboussin DM, DeMets DL, Kim KM, Lan KKG. Programs for computing group sequential boundaries using the Lan-DeMets method. Technical Report, Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, 1996.
23. EAST version 5.1. Cytel Software Corporation: Cambridge, MA, 2007.
24. Schervish MJ. Multivariate normal probabilities with error bound. Applied Statistics 1984; 33:81-94.
25. Chen YHJ, Anderson KM. A 'MiniPool' approach for combined phase IIB/III trial in patients with life-threatening disease: an application of the closed testing principle. Statistics in Biopharmaceutical Research 2010; 2:62-71.
26. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: the PURSUIT Trial Investigators: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression using Integrilin Therapy. The New England Journal of Medicine 1998; 339:436-443.
27. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal 2009; 157:805-810.
28. DeMets DL. Futility approaches to interim monitoring by data monitoring committees. Clinical Trials 2006; 3:522-529.
29. Schoenfeld DA, Meade MO. Pro/con clinical debate: it is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Critical Care 2005; 9:34-36.
30. Stallard N, Friede T. A group-sequential design for clinical trials with treatment selection. Statistics in Medicine 2008; 27:6209-6227.